These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24758726)

  • 1. Eruptive cutaneous squamous cell carcinoma and psoriasis: response to cetuximab.
    Kamaria M; Shea CR; Chin RK; Cohen EE; Maggiore R; Bolotin D
    Clin Exp Dermatol; 2014 Jul; 39(5):604-7. PubMed ID: 24758726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of cetuximab for non-melanoma skin cancer.
    Wollina U
    Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful combination therapy of a locally advanced squamous cell carcinoma of the skin with cetuximab and γ-irradiation.
    Göppner D; Nekwasil S; Franke I; Gollnick H; Leverkus M
    J Dtsch Dermatol Ges; 2010 Oct; 8(10):826-8. PubMed ID: 20731754
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecularly targeted therapies for nonmelanoma skin cancers.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 Jun; 52(6):654-65. PubMed ID: 23679874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma--a report of eight cases.
    Giacchero D; Barrière J; Benezery K; Guillot B; Dutriaux C; Mortier L; Lacour JP; Thyss A; Peyrade F
    Clin Oncol (R Coll Radiol); 2011 Dec; 23(10):716-8. PubMed ID: 21831617
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors.
    Alter M; Satzger I; Mattern A; Kapp A; Gutzmer R
    Dermatology; 2013; 227(4):289-94. PubMed ID: 24217470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab.
    Suen JK; Bressler L; Shord SS; Warso M; Villano JL
    Anticancer Drugs; 2007 Aug; 18(7):827-9. PubMed ID: 17581306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma.
    Kim M; Li M; Intong LR; Tran K; Melbourne W; Marucci D; Bucci J; de Souza P; Mallesara G; Murrell DF
    Br J Dermatol; 2013 Jul; 169(1):208-10. PubMed ID: 23398414
    [No Abstract]   [Full Text] [Related]  

  • 9. Imiquimod cream 5% for the treatment of arsenic-induced cutaneous neoplasms.
    Lonergan CL; McNamara EK; Cordoro KM; Greer KE
    Cutis; 2010 Apr; 85(4):199-202. PubMed ID: 20486460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.
    Chang AL; Kim J; Luciano R; Sullivan-Chang L; Colevas AD
    JAMA Dermatol; 2016 Jan; 152(1):106-8. PubMed ID: 26422398
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of cetuximab in the treatment of squamous cell carcinoma.
    Preneau S; Rio E; Brocard A; Peuvrel L; Nguyen JM; Quéreux G; Dreno B
    J Dermatolog Treat; 2014 Oct; 25(5):424-7. PubMed ID: 23167307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab in non-melanoma skin cancer.
    Wollina U
    Expert Opin Biol Ther; 2012 Jul; 12(7):949-56. PubMed ID: 22519406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report.
    Falivene S; Giugliano FM; Grimaldi AM; Di Franco R; Toledo D; Muto M; Cammarota F; Borzillo V; Ascierto PA; Muto P
    BMC Dermatol; 2014 Sep; 14():15. PubMed ID: 25270710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck.
    Kim S; Eleff M; Nicolaou N
    Head Neck; 2011 Feb; 33(2):286-8. PubMed ID: 19953623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.
    Bauman JE; Eaton KD; Martins RG
    Arch Dermatol; 2007 Jul; 143(7):889-92. PubMed ID: 17638733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma.
    Miller K; Sherman W; Ratner D
    Dermatol Surg; 2010 Dec; 36(12):2069-74. PubMed ID: 21044226
    [No Abstract]   [Full Text] [Related]  

  • 17. Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients.
    Boyd K; Shea SM; Patterson J
    Wien Med Wochenschr; 2013 Aug; 163(15-16):372-5. PubMed ID: 23800851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.
    Winkler JK; Schneiderbauer R; Bender C; Sedlaczek O; Fröhling S; Penzel R; Enk A; Hassel JC
    Br J Dermatol; 2017 Feb; 176(2):498-502. PubMed ID: 27061826
    [No Abstract]   [Full Text] [Related]  

  • 19. An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma.
    O'Bryan K; Sherman W; Niedt GW; Taback B; Manolidis S; Wang A; Ratner D
    J Am Acad Dermatol; 2013 Oct; 69(4):595-602.e1. PubMed ID: 23871719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma.
    Antar A; Ishak RS; Otrock ZK; El-Majzoub N; Ghosn S; Mahfouz R; Taher AT
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):166-9. PubMed ID: 25467031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.